Simiso Sokhela

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

François Venter, Michelle Moorhouse, Simiso Sokhela et al. · New England Journal of Medicine · 2019 · 684 citations · Full text

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

François Venter, Simiso Sokhela, Bryony Simmons et al. · The Lancet HIV · 2020 · 249 citations

Week 96, Treatment And Prevention, Antiviral Drug Development +9

<i>CYP2B6</i> Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz

Rulan Griesel, Gary Maartens, Maxwell Chirehwa et al. · Clinical Infectious Diseases · 2020 · 81 citations · Full text

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial

Cissy Kityo, Ivan Mambule, Joseph Musaazi et al. · The Lancet Infectious Diseases · 2024 · 81 citations · Full text

Sexual Health, Health Sciences, Treatment And Prevention +14

Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes

Kaitlyn McCann, Shahini Shah, Laura Hindley et al. · AIDS · 2021 · 70 citations